Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Nuvectis Pharma is offering 5,000,000 shares of common stock at $20.00 per share. The offering is expected to raise approximately $100,000,000 before underwriting discounts, with estimated net proceeds to the company of about $93,000,000. The underwriters have an option to purchase an additional 750,000 shares.
Proceeds are intended to fund development of NXP100, NXP200 and NXP900, hiring, capital expenditures and general corporate purposes. The Haisco license agreement tied to NXP100 and NXP200 is subject to certain financing conditions and a required financing milestone.
Nuvectis Pharma, Inc. is offering shares of its common stock under a preliminary prospectus supplement dated June 29, 2026. The offering is a registered primary sale of common stock on Nasdaq (symbol NVCT), with an underwriter option to purchase additional shares for 30 days.
The supplement discloses a June 22, 2026 license agreement with Haisco providing Nuvectis exclusive rights (outside specified Asian territories) to develop, manufacture and commercialize NXP100 and NXP200, subject to financing conditions. Consideration includes a $20 million upfront payment, up to $20 million initial development milestones, up to $1.4 billion contingent milestones and tiered royalties.
Nuvectis Pharma, Inc. reported a change to its existing at-the-market stock sales arrangement with Leerink Partners. The company lowered the amount available for sales under its Sales Agreement prospectus to $5 million, meaning it can offer and sell up to that value of common stock over time.
At the same time, Nuvectis is suspending use of the current Sales Agreement prospectus and will not sell any shares under this arrangement unless and until a new prospectus, prospectus supplement, or registration statement is filed. The underlying Sales Agreement with Leerink Partners remains in full force and effect.
Nuvectis Pharma entered a strategic license agreement with Haisco Pharmaceutical Group for exclusive rights outside China (with certain Asia carve-outs) to two clinical-stage drugs, NXP100 and NXP200. Nuvectis will lead development, manufacturing, and commercialization in its territory, while Haisco continues current work in China.
As consideration, Nuvectis will pay Haisco an upfront $20 million, with up to $20 million in initial development milestones and up to an additional $1.4 billion tied to future development, regulatory, and commercial milestones, plus tiered high-single-digit to mid-teens royalties on net sales. The agreement is subject to financing conditions to ensure Nuvectis has sufficient capital to advance the programs.
NXP100 is a late-stage oral Complement Factor B inhibitor with positive Phase 3 data in paroxysmal nocturnal hemoglobinuria and supportive Phase 2 data in IgA nephropathy, while NXP200 is a brain-penetrant, paradox-breaker BRAF inhibitor with early signals of durable activity across several BRAF-mutated solid tumors.
Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma, Inc. director Kenneth Hoberman received a grant of 35,000 shares of restricted common stock. The award was granted at no cash cost per share and is a form of equity compensation rather than an open-market purchase.
The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Hoberman continues serving on the company’s Board of Directors. After this grant, he directly holds 168,140 shares of common stock, which includes restricted shares.
Oliviero James F III reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director James F. Oliviero III received a grant of 35,000 shares of restricted common stock. These shares were awarded at no cash cost to him and are part of his equity compensation.
The restricted stock will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the company’s Board of Directors. Following this grant, he holds a total of 122,828 shares of Nuvectis Pharma common stock, including restricted shares.
Sanchez Juan reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director Juan Sanchez received a grant of 35,000 shares of restricted common stock at no cost. The award will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the Board of Directors.
After this grant, Sanchez holds 113,380 common shares directly and 415 shares indirectly as custodian for his son. The filing also notes that his current holdings include 230 restricted shares that had been inadvertently omitted from his earlier Form 3.
Kaplan Matthew L. reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director Matthew L. Kaplan received a grant of 35,000 shares of restricted common stock. The award was made at no cash cost per share and is classified as a compensation-related grant rather than an open-market purchase.
The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Kaplan continues to serve on the Board of Directors on those dates. After this grant, he directly holds 159,760 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma, Inc. reported the results of its 2026 Annual Meeting and corrected a share count error in its proxy. The Definitive Proxy Statement had stated 27,668,036 common shares outstanding as of April 13, 2026; the correct number was 26,614,628 shares.
The company stated this correction does not affect the validity or outcome of any votes. Stockholders representing 16,193,686 shares, or 60.8% of the 26,614,628 shares outstanding on the record date, were present, establishing a quorum. Stockholders elected Class I director Ron Bentsur and ratified Kesselman & Kesselman as independent registered public accounting firm for the year ending December 31, 2026.
Nuvectis Pharma reported first-quarter 2026 results, continuing as a clinical-stage oncology company with no product revenue. Net loss was $6.1 million, compared with $5.3 million a year earlier, driven by higher research and development and public-company costs.
Research and development expenses were $4.1 million and general and administrative expenses were $2.2 million. Cash and cash equivalents totaled $25.1 million at March 31 2026, which management believes can fund operations for at least 12 months.
The accumulated deficit reached $105.7 million. Shares outstanding rose to 26,525,533, reflecting equity-based compensation and modest use of the at-the-market program, which still has $60.0 million capacity within a broader $150.0 million shelf registration. Lead asset NXP900 remains in Phase 1b development.